Literature DB >> 1378075

Soluble forms of CD40 inhibit biologic responses of human B cells.

W C Fanslow1, D M Anderson, K H Grabstein, E A Clark, D Cosman, R J Armitage.   

Abstract

We have expressed the CD40 surface Ag as both a soluble 28-kDa molecule and a 57-kDa Fc fusion protein containing the human IgG1 Fc region. Soluble CD40 and the Fc fusion protein inhibited the proliferative response of anti-IgM-activated human B cells to the CD40 mAb G28-5. Similarly, G28-5- and IL-4-induced IgE secretion from PBMC depleted of T cells was effectively blocked by both forms of soluble CD40. Although the soluble constructs of CD40 had only a minimal inhibitory effect on IL-4-mediated proliferation of anti-IgM-activated B cells, IL-4-induced soluble CD23 shedding from both PBMC and T cells depleted of PBMC, and IgE secretion from PBMC, were significantly reduced in a concentration-dependent manner when soluble CD40 was present in the culture. The data presented demonstrate that both soluble forms of the CD40 molecule are biologically active, and suggest that the ligand for CD40 is inducible in IL-4-stimulated cultures and that it mediates both shedding of sCD23 and IgE secretion.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1378075

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  40 in total

1.  Multivalent recombinant proteins for probing functions of leucocyte surface proteins such as the CD200 receptor.

Authors:  Despina Voulgaraki; Rita Mitnacht-Kraus; Michelle Letarte; Mildred Foster-Cuevas; Marion H Brown; A Neil Barclay
Journal:  Immunology       Date:  2005-07       Impact factor: 7.397

2.  Defective expression of the CD40 ligand in X chromosome-linked immunoglobulin deficiency with normal or elevated IgM.

Authors:  R Fuleihan; N Ramesh; R Loh; H Jabara; R S Rosen; T Chatila; S M Fu; I Stamenkovic; R S Geha
Journal:  Proc Natl Acad Sci U S A       Date:  1993-03-15       Impact factor: 11.205

Review 3.  The biology of the human ligand for CD40.

Authors:  M K Spriggs; W C Fanslow; R J Armitage; J Belmont
Journal:  J Clin Immunol       Date:  1993-11       Impact factor: 8.317

Review 4.  The hyper-IgM (HIM) syndrome.

Authors:  N Ramesh; M Seki; L D Notarangelo; R S Geha
Journal:  Springer Semin Immunopathol       Date:  1998

5.  Locomotor properties of human germinal centre B cells: activation by anti-CD40 and IL-4 allows chemoattraction by anti-immunoglobulin.

Authors:  M Komai-Koma; P C Wilkinson
Journal:  Immunology       Date:  1997-01       Impact factor: 7.397

6.  The Epstein-Barr virus BARF1 gene encodes a novel, soluble colony-stimulating factor-1 receptor.

Authors:  L D Strockbine; J I Cohen; T Farrah; S D Lyman; F Wagener; R F DuBose; R J Armitage; M K Spriggs
Journal:  J Virol       Date:  1998-05       Impact factor: 5.103

7.  Humoral immune responses in CD40 ligand-deficient mice.

Authors:  B R Renshaw; W C Fanslow; R J Armitage; K A Campbell; D Liggitt; B Wright; B L Davison; C R Maliszewski
Journal:  J Exp Med       Date:  1994-11-01       Impact factor: 14.307

8.  Epstein-Barr virus uses different complexes of glycoproteins gH and gL to infect B lymphocytes and epithelial cells.

Authors:  X Wang; W J Kenyon; Q Li; J Müllberg; L M Hutt-Fletcher
Journal:  J Virol       Date:  1998-07       Impact factor: 5.103

9.  Development and in vitro characterization of canine CD40-Ig.

Authors:  Christoph Jochum; Mechthild Beste; Diane Stone; Scott S Graves; Rainer Storb
Journal:  Vet Immunol Immunopathol       Date:  2008-02-16       Impact factor: 2.046

10.  Glucocorticoids upregulate CD40 ligand expression and induce CD40L-dependent immunoglobulin isotype switching.

Authors:  H H Jabara; S R Brodeur; R S Geha
Journal:  J Clin Invest       Date:  2001-02       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.